Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

(2022) Henry N. Ginsberg et al.   DIABETES CARE

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

(2021) Atsushi Nakajima et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

(2021) Henry N Ginsberg et al.   EUROPEAN HEART JOURNAL

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

(2021) Shizuya Yamashita et al.   Journal of Atherosclerosis and Thrombosis

Diabetes Associated Residual Atherosclerotic Cardiovascular Risk in Statin-Treated Patients with Prior Atherosclerotic Cardiovascular Disease

(2020) Yanglu Zhao et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

(2020) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

(2018) Eiichi Araki et al.   DIABETES CARE

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

(2018) Shun Ishibashi et al.   Journal of Clinical Lipidology

Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol

(2018) Gregory A. Nichols et al.   DIABETES OBESITY & METABOLISM

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

(2018) Aruna D. Pradhan et al.   AMERICAN HEART JOURNAL

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

(2017) Marshall B. Elam et al.   JAMA Cardiology

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

(2016) Shun Ishibashi et al.   ATHEROSCLEROSIS

Triglycerides and cardiovascular disease

(2014) Børge G Nordestgaard et al.   LANCET

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

A general inefficacy interim monitoring rule for randomized clinical trials

(2010) Boris Freidlin et al.   Clinical Trials

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

(2010) Elisa Fabbrini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE